Trial Profile
Efficacy of rivaroxaban versus vitamin K antagonists in preventing recurrent venous thromboembolism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Oct 2015
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Venous thromboembolism
- Focus Therapeutic Use
- 20 Oct 2015 New trial record
- 02 Sep 2015 Results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.